Percheron CEO on positive HMBD-002 trial data

24 Visioni

  • Grazie! Condividilo con i tuoi amici!

    Non hai gradito questo video. Grazie per il feedback!

admin
Published
Percheron Therapeutics Ltd (ASX:PER, OTC:PERCF) CEO Dr James Garner talked with Proactive about the company’s latest milestone — final results from the Phase I clinical trial of its cancer drug candidate, HMBD-002.

Garner confirmed the study achieved its primary objective, demonstrating a favourable safety profile in 48 patients with advanced cancers. The treatment was assessed both as a monotherapy and in combination with an existing cancer therapy. “The drug passed all these hurdles, ticked every box,” said Garner, who called the results “tremendously reassuring.”

Only a small minority — fewer than 10% — of patients experienced any significant side effects. Even these were described as potentially related to the underlying cancer itself, rather than the treatment. “This is about as clean a bill of health as we could get,” said Garner.

The company is now preparing for a Phase II trial, scheduled to begin in the 2026 calendar year. Unlike the first trial, which focused on safety, the upcoming study will evaluate HMBD-002’s efficacy more directly. Garner noted that early signs of activity were observed in Phase I, despite the study not being powered for efficacy assessment.

To stay up to date with more clinical updates and executive interviews, visit Proactive’s YouTube channel. Don’t forget to give this video a like, subscribe to the channel, and enable notifications for future content.

#PercheronTherapeutics #HMBD002 #ClinicalTrials #CancerResearch #BiotechStocks #ASXPER #OTCPERCF #Immunotherapy #Oncology #BiotechNews
Categoria
Oncology
Commenta per primo questo video.

Prossimo